Literature DB >> 20951783

Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.

Yasemin Cırpanlı1, Emilie Allard, Catherine Passirani, Erem Bilensoy, Laurent Lemaire, Sema Calış, Jean-Pierre Benoit.   

Abstract

Camptothecin (CPT), a plant alkaloid, is a potent anticancer drug in cell culture studies but it is clinically inactive due to rapid hydrolysis under physiological conditions. The drug exists in two forms depending on the pH value, an active lactone form at pH below 5 and an inactive carboxylate form at basic pH and this is a reversible reaction. In this study, nanoparticulate delivery systems were developed with either amphiphilic cyclodextrins, poly(lactide-co-glycolide) or poly-ɛ-caprolactone in order to maintain the active lactone form and prevent the drug from hydrolysis. All nanoparticles were prepared with nanoprecipitation technique. Mean particle sizes were 130-280nm and surface charges were negative. The encapsulation efficiency was significantly higher for amphiphilic cyclodextrin nanoparticles when compared to polymeric nanoparticles. Nanoparticle formulations based on cyclodextrins showed a controlled release profile extended up to 12 days. 6-O-Capro-β-cyclodextrin (1.44μg/60μL CPT) and concentrated 6-O-Capro-β-cyclodextrin (2.88μg/60μL CPT) nanoparticles significantly modified the growth or lethality of the 9L gliomas, since the median survival time was 26 days for the untreated group and between 27 and 33 days for amphiphilic cyclodextrin nanoparticle groups. These results indicate that, CPT-loaded amphiphilic cyclodextrin nanoparticles may provide a promising carrier system for the effective delivery of CPT in comparison to polymeric analogues.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951783     DOI: 10.1016/j.ijpharm.2010.10.015

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  13 in total

Review 1.  Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles.

Authors:  Francesca Pistollato; Susanne Bremer-Hoffmann; Giuseppe Basso; Sandra Sumalla Cano; Iñaki Elio; Manuel Masias Vergara; Francesca Giampieri; Maurizio Battino
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

Review 2.  Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.

Authors:  Rajneet K Oberoi; Karen E Parrish; Terence T Sio; Rajendar K Mittapalli; William F Elmquist; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2015-09-10       Impact factor: 12.300

Review 3.  Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review.

Authors:  Maryam Ghanbari-Movahed; Tea Kaceli; Arijit Mondal; Mohammad Hosein Farzaei; Anupam Bishayee
Journal:  Biomedicines       Date:  2021-04-27

4.  Poly ɛ-caprolactone nanoparticles loaded with Uncaria tomentosa extract: preparation, characterization, and optimization using the Box-Behnken design.

Authors:  Ana Ferreira Ribeiro; Ricardo Leite de Oliveira Rezende; Lúcio Mendes Cabral; Valéria Pereira de Sousa
Journal:  Int J Nanomedicine       Date:  2013-01-25

5.  Fabrication and optimization of camptothecin loaded Eudragit S 100 nanoparticles by Taguchi L4 orthogonal array design.

Authors:  Manikandan Mahalingam; Kannan Krishnamoorthy
Journal:  Int J Pharm Investig       Date:  2015 Jul-Sep

Review 6.  Particles from preformed polymers as carriers for drug delivery.

Authors:  K Miladi; D Ibraheem; M Iqbal; S Sfar; H Fessi; A Elaissari
Journal:  EXCLI J       Date:  2014-02-03       Impact factor: 4.068

7.  Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects.

Authors:  Dhruba J Bharali; Imtiaz A Siddiqui; Vaqar M Adhami; Jean Christopher Chamcheu; Abdullah M Aldahmash; Hasan Mukhtar; Shaker A Mousa
Journal:  Cancers (Basel)       Date:  2011-10-26       Impact factor: 6.639

8.  PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system.

Authors:  Paula M Castillo; Mario de la Mata; Maria F Casula; José A Sánchez-Alcázar; Ana P Zaderenko
Journal:  Beilstein J Nanotechnol       Date:  2014-08-19       Impact factor: 3.649

9.  Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.

Authors:  Chien-Ju Lin; Yi-Ling Lin; Frank Luh; Yun Yen; Ruei-Ming Chen
Journal:  Oncotarget       Date:  2016-07-05

10.  Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment.

Authors:  Cem Varan; Erem Bilensoy
Journal:  Beilstein J Nanotechnol       Date:  2017-07-12       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.